TROP2 ADC Hits Phase 3 Bullseye; Regeneron Bets Big on "Undruggable" Targets
May 19, 2026 07:32
CST Updated
10:24
Kelun-Biotech
Innovative Drug Developer
Parabilis Medicines
Developer of New Anti-Cancer Drugs